<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

AS 602801 - Bentamapimod

產(chǎn)品貨號(hào)

Axon 2002 CAS [848344-36-5] MF C25H23N5O2SMW 457.55 Purity: 98% Soluble in 0.1N HCl(aq) and DMSO Description Potent, orally active and selective Jun kinase (JNK) inhibitor, which inhibited JNK1, JNK2 and JNK3 with IC50 values of 80, 90 and 230 nM respectively. It blocked T-lymphocyte proliferation and induced apoptosis References Certificates Categories Extra info S Halazy. Designing heterocyclic selective kinase inhibitors: from concept to new drug candidates. ARKIVOC 2006 (vii) 496-508.? ? C Chiara Ferrandi et al. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Mult. Scler. J. 2011, 17(1), 43-56.? ? SS Bhagwat. Chapter 17 MAP Kinase Inhibitors in Inflammation and Autoimmune Disorders. Ann. Rep. Med. Chem. 2007, 42, 265-278.? Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Signaling & Oncology Immunology Pain & Inflammation MAPK (JNK) p53-Tumor Suppression NF-κB MAPK EC 2.7.11.24 JNK inhibitor, which inhibited JNK1, JNK2 and JNK3 Chemical name 2-(benzo[d]thiazol-2-yl)-2-(2-(4-(morpholinomethyl)benzyloxy)pyrimidin-4-yl)acetonitrile Parent CAS No. [848344-36-5] Order Size Unit Price Stock 5 mg €120.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

AS 602801 - Bentamapimod

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2002

CAS [848344-36-5]

MF C25H23N5O2S
MW 457.55

Purity: 98%
Soluble in 0.1N HCl(aq) and DMSO

AS 602801

Description

Potent, orally active and selective Jun kinase (JNK) inhibitor, which inhibited JNK1, JNK2 and JNK3 with IC50 values of 80, 90 and 230 nM respectively. It blocked T-lymphocyte proliferation and induced apoptosis

S Halazy. Designing heterocyclic selective kinase inhibitors: from concept to new drug candidates. ARKIVOC 2006 (vii) 496-508.?

C Chiara Ferrandi et al. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Mult. Scler. J. 2011, 17(1), 43-56.?

SS Bhagwat. Chapter 17 MAP Kinase Inhibitors in Inflammation and Autoimmune Disorders. Ann. Rep. Med. Chem. 2007, 42, 265-278.?

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Signaling & Oncology Immunology Pain & Inflammation MAPK (JNK) p53-Tumor Suppression NF-κB MAPK EC 2.7.11.24

JNK inhibitor, which inhibited JNK1, JNK2 and JNK3

Chemical name

2-(benzo[d]thiazol-2-yl)-2-(2-(4-(morpholinomethyl)benzyloxy)pyrimidin-4-yl)acetonitrile

Parent CAS No.

[848344-36-5]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>